4-aminopyridine has been researched along with Eaton-Lambert Myasthenic Syndrome in 60 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the efficacy and safety of amifampridine phosphate (Firdapse(®)) for symptomatic treatment in Lambert-Eaton myasthenic syndrome (LEMS)." | 5.22 | Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS. ( Alsharabati, M; Blanco, JM; Brannagan, T; Dimachkie, M; Komoly, S; Kostera-Pruszczyk, A; Lavrnić, D; Meisel, A; Oh, SJ; Schoser, B; Shcherbakova, N; Shieh, PB; Sivakumar, K; So, Y; Vial, C, 2016) |
| "3,4-diaminopyridine (3,4-DAP; amifampridine) is used for symptomatic treatment of Lambert-Eaton myasthenic syndrome." | 3.78 | Content variability of active drug substance in compounded oral 3,4-diaminopyridine products. ( Brain, KR; Green, DM; Jones, AC, 2012) |
| "We describe a patient with respiratory failure secondary to LEMS who responded to 3,4-diaminopyridine and review the 12 previously reported cases of ventilatory failure in LEMS." | 2.39 | Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine. ( Smith, AG; Wald, J, 1996) |
| " The daily dosage ranged from 36 to 100 mg." | 1.48 | [A retrospective study of the effects of 3,4-diaminopyridine treatment in Lambert-Eaton myasthenic syndrome]. ( Kano, T; Matsushima, M; Naganuma, R; Sasaki, H; Takahashi, I; Yabe, I, 2018) |
| "We report a patient with neurogenic bladder secondary to LEMS whose condition responded to 3,4-diaminopyridine (3,4-DAP)." | 1.31 | Neurogenic bladder in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine. ( Eguchi, K; Fujimoto, T; Fukuda, T; Motomura, M; Nakamura, T; Nakane, S; Nakao, Y; Satoh, K; Suzu, H, 2001) |
| "Side-effects included initial perioral paresthesia and, later, paresthesia down the skin and along the ulnar edge of the forearm." | 1.28 | [Long-term treatment of Lambert-Eaton syndrome by 3, 4 diaminopyridine]. ( Forrett-Kaminsky, MC; Jost, WH; Mielke, U; Schimrigk, K, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.67) | 18.7374 |
| 1990's | 24 (40.00) | 18.2507 |
| 2000's | 14 (23.33) | 29.6817 |
| 2010's | 19 (31.67) | 24.3611 |
| 2020's | 2 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, N | 1 |
| Hong, D | 1 |
| Ouyang, T | 1 |
| Meng, W | 1 |
| Huang, J | 1 |
| Li, M | 1 |
| Hong, T | 1 |
| De Giglio, L | 1 |
| Cortese, F | 1 |
| Pennisi, EM | 1 |
| Thakkar, N | 1 |
| Guptill, JT | 1 |
| Aleš, K | 1 |
| Jacobus, D | 1 |
| Jacobus, L | 1 |
| Peloquin, C | 1 |
| Cohen-Wolkowiez, M | 1 |
| Gonzalez, D | 1 |
| Portaro, S | 1 |
| Brizzi, T | 1 |
| Sinicropi, S | 1 |
| Cacciola, A | 1 |
| De Cola, MC | 1 |
| Bramanti, A | 1 |
| Milardi, D | 1 |
| Lupica, A | 1 |
| Bramanti, P | 1 |
| Toscano, A | 1 |
| Rodolico, C | 1 |
| de Wilde, S | 1 |
| de Jong, MGH | 1 |
| Lipka, AF | 1 |
| Guchelaar, HJ | 1 |
| Schimmel, KJM | 1 |
| Naganuma, R | 1 |
| Yabe, I | 2 |
| Takahashi, I | 1 |
| Matsushima, M | 2 |
| Kano, T | 1 |
| Sasaki, H | 2 |
| Lee, MK | 1 |
| Sunwoo, IN | 1 |
| Kim, SM | 1 |
| Oh, SJ | 5 |
| Tarr, TB | 1 |
| Lacomis, D | 1 |
| Reddel, SW | 1 |
| Liang, M | 1 |
| Valdomir, G | 1 |
| Frasso, M | 1 |
| Wipf, P | 1 |
| Meriney, SD | 1 |
| Schneider, I | 1 |
| Kornhuber, ME | 1 |
| Hanisch, F | 1 |
| Shcherbakova, N | 1 |
| Kostera-Pruszczyk, A | 1 |
| Alsharabati, M | 1 |
| Dimachkie, M | 1 |
| Blanco, JM | 1 |
| Brannagan, T | 1 |
| Lavrnić, D | 1 |
| Shieh, PB | 1 |
| Vial, C | 1 |
| Meisel, A | 1 |
| Komoly, S | 1 |
| Schoser, B | 1 |
| Sivakumar, K | 1 |
| So, Y | 1 |
| Chan, KY | 1 |
| Chang, RS | 1 |
| Lau, VW | 1 |
| Chan, ML | 1 |
| Lai, T | 1 |
| Uekita, K | 1 |
| Ishida, T | 1 |
| Sekine, S | 1 |
| Ishii, T | 1 |
| Sato, S | 1 |
| Sugawara, A | 1 |
| Tachihara, M | 1 |
| Watanabe, K | 1 |
| Kanazawa, K | 1 |
| Saito, J | 1 |
| Tanino, Y | 1 |
| Munakata, M | 1 |
| Wirtz, PW | 3 |
| Verschuuren, JJ | 4 |
| van Dijk, JG | 1 |
| de Kam, ML | 1 |
| Schoemaker, RC | 1 |
| van Hasselt, JG | 1 |
| Titulaer, MJ | 4 |
| Tjaden, UR | 1 |
| den Hartigh, J | 1 |
| van Gerven, JM | 1 |
| Claussen, GG | 1 |
| Hatanaka, Y | 1 |
| Morgan, MB | 1 |
| Quartel, A | 2 |
| Turbeville, S | 1 |
| Lounsbury, D | 1 |
| Suzuki, S | 1 |
| Gerven, JM | 1 |
| Lennertz, J | 1 |
| Keogh, M | 1 |
| Sedehizadeh, S | 1 |
| Maddison, P | 6 |
| Green, DM | 1 |
| Jones, AC | 1 |
| Brain, KR | 1 |
| Lang, B | 2 |
| Giovannini, F | 1 |
| Sher, E | 1 |
| Webster, R | 1 |
| Boot, J | 1 |
| Newsom-Davis, J | 7 |
| Willems, LN | 1 |
| van Gerven, J | 1 |
| Sha, SJ | 1 |
| Layzer, RB | 1 |
| Yaguchi, H | 1 |
| Kishimoto, R | 1 |
| Tsuji, S | 1 |
| Nakadate, M | 1 |
| Shiraishi, H | 1 |
| Motomura, M | 2 |
| Shipley, E | 1 |
| Krim, E | 1 |
| Deminière, C | 1 |
| Lagueny, A | 1 |
| Boerma, CE | 1 |
| Rommes, JH | 1 |
| van Leeuwen, RB | 1 |
| Bakker, J | 1 |
| Morata, C | 1 |
| Alfaro, A | 1 |
| Chumillas, MJ | 1 |
| Montalar, J | 1 |
| Cooke, JD | 1 |
| Hefter, H | 1 |
| Brown, SH | 1 |
| Toyka, KV | 1 |
| Freund, HJ | 1 |
| Lundh, H | 1 |
| Nilsson, O | 1 |
| Rosén, I | 1 |
| Johansson, S | 1 |
| Sanders, DB | 4 |
| Howard, JF | 1 |
| Massey, JM | 3 |
| Casanova, B | 2 |
| Vílchez, JJ | 2 |
| Rubio, P | 1 |
| Molgó, J | 1 |
| Guglielmi, JM | 1 |
| Monte, E | 1 |
| Smith, AG | 1 |
| Wald, J | 1 |
| Sadeh, M | 1 |
| River, Y | 1 |
| Argov, Z | 1 |
| Kim, DS | 2 |
| Claussen, GC | 2 |
| Tim, RW | 2 |
| Kwon, KH | 1 |
| Tseng, A | 1 |
| Mussell, H | 1 |
| Mills, KR | 2 |
| Seneviratne, U | 1 |
| de Silva, R | 1 |
| Satoh, K | 1 |
| Suzu, H | 1 |
| Nakao, Y | 1 |
| Fujimoto, T | 1 |
| Fukuda, T | 1 |
| Nakane, S | 1 |
| Nakamura, T | 1 |
| Eguchi, K | 1 |
| Oishi, K | 1 |
| Oya, Y | 1 |
| Yamamoto, T | 1 |
| Shigeto, H | 1 |
| Ogawa, M | 1 |
| Kawai, M | 1 |
| Jost, WH | 2 |
| Mielke, U | 2 |
| Forrett-Kaminsky, MC | 1 |
| Schimrigk, K | 2 |
| Telford, RJ | 1 |
| Hollway, TE | 1 |
| Chalk, CH | 1 |
| Murray, NM | 1 |
| O'Neill, JH | 1 |
| Spiro, SG | 1 |
| Manji, H | 1 |
| Schwartz, MS | 1 |
| McKeran, RO | 1 |
| Sahashi, K | 1 |
| McEvoy, KM | 1 |
| Windebank, AJ | 1 |
| Daube, JR | 1 |
| Low, PA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy.[NCT01522235] | Phase 2/Phase 3 | 6 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Phase 2 Study of 4-Aminopyridine for the Treatment of Episodic Ataxia Type 2[NCT01543750] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome, the change in systolic blood pressure during 60 degree tilt (ΔSBP), will be assessed in all study participants at baseline and at 6 weeks. (NCT01522235)
Timeframe: Baseline and 6 weeks
| Intervention | mmHg (Mean) |
|---|---|
| IVIg Group | 42.5 |
| Placebo Group | -12.3 |
To compare the change in systolic blood pressure during 60 degree head up tilt table test after 6 and 12 weeks of IVIG (the within-patient difference in ΔSBP at 12 and 6 weeks among treated patients). (NCT01522235)
Timeframe: 6 weeks and 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| IVIG Group | -26 |
| Placebo Group | -7.6 |
"To determine the change in autonomic symptoms (measured by the composite autonomic severity score [CASS]) measured at baseline and 6 weeks in individuals receiving IVIg.~Is a 10-point composite autonomic scoring scale of autonomic function. This scale allots 4 points for adrenergic and 3 points each for sudomotor and cardiovagal failure. Subjects with a score of 3 or less on have a mild autonomic failure, 4-6 have moderate autonomic failure and those with scores of 7 to 10 have severe failure. The minimum score possible is 3 and maximum is 10." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| IVIg Group | 0.5 |
| Placebo Group | 0 |
To determine the change in autonomic symptoms (measured by the composite autonomic symptom score [COMPASS] questionnaire) measured at baseline and 6 weeks. Minimum and maximum score possible: 0-100. We have reported the Total score. Higher values represent worse outcome. (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| IVIg Group | -5 |
| Placebo Group | -0.33 |
"To determine the change in quality of life (measured by the EuroQol [EQ-5D]) measured at baseline and 6 weeks in individuals receiving IVIg. We have reported the subscale (EQ-VAS). The minimum score is 0 and maximum score is 100. (0) corresponds to the worst health you can imagine, and the highest rate (100) corresponds to the best health you can imagine." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| IVIg Group | 15 |
| Placebo Group | 9.3 |
"To determine the change in orthostatic Hypotension symptom (measured by the orthostatic hypotension symptom assessment questionnaire) measured at baseline and 6 weeks in individuals receiving IVIG. This is a 60 point orthostatic hypotenstion symptom assessment questionnaire. The minimum score possible is 0 and maximum is 60.~Higher values represent worse outcome. We are reporting the total score." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| Group A | -9 |
| Group B | 12 |
14 reviews available for 4-aminopyridine and Eaton-Lambert Myasthenic Syndrome
| Article | Year |
|---|---|
3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials.
Topics: 4-Aminopyridine; Adult; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Myasthenia Gravis; | 2021 |
Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Antineoplastic Agents; Humans; Lambert-Eaton Myasthenic | 2010 |
[Lambert-Eaton myasthenic syndrome (LEMS)].
Topics: 4-Aminopyridine; Amifampridine; Autoantibodies; Calcium Channels, P-Type; Calcium Channels, Q-Type; | 2010 |
3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Calcium Channels; Cholinergic Agents; Clinical Pr | 2010 |
Treatment for Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Cholinesterase Inhibitors; Humans; Immunoglobulins, Intravenous; Lam | 2011 |
Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
Topics: 4-Aminopyridine; Amifampridine; Autoantibodies; Calcium Channels; Carcinoma, Small Cell; Humans; Lam | 2011 |
Treatment in Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Antineoplastic Agents; Guanidine; Humans; Immunoglobulins, Intraveno | 2012 |
Treatment for Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Humans; Immunoglobulins, Intravenous; Lambert-Eaton Myasthenic Syndr | 2003 |
Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Autoantibodies; Autoantigens; Autoimmune Diseases of the Nervous Sys | 2004 |
Treatment for Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Humans; Immunoglobulins, Intravenous; Lambert-Eaton Myasthenic Syndrome; Potassium | 2005 |
Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Antineoplastic Agents; Carcinoma, Small Cell; Cholinesterase Inhibitors; Cisplatin; | 2006 |
3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Orphan Drug Production; P | 1996 |
Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Acute Disease; Amifampridine; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Mi | 1996 |
Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Anti-Inflammatory Agents; Autoantibodies; Calcium Channels; Carcinom | 1999 |
6 trials available for 4-aminopyridine and Eaton-Lambert Myasthenic Syndrome
| Article | Year |
|---|---|
Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.
Topics: 4-Aminopyridine; Adult; Aged; Aged, 80 and over; Amifampridine; Arylamine N-Acetyltransferase; Femal | 2017 |
Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.
Topics: 4-Aminopyridine; Adult; Aged; Aged, 80 and over; Amifampridine; Calcium Channels; Double-Blind Metho | 2016 |
Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Cross-Over Studies; Double-Blind Method; Drug Therapy, | 2009 |
3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Cross-Over Studies; Double-Blind Method; Female; Humans | 2009 |
3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis.
Topics: 4-Aminopyridine; Amifampridine; Double-Blind Method; Humans; Lambert-Eaton Myasthenic Syndrome; Myas | 1993 |
3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Action Potentials; Adult; Aged; Amifampridine; Clinical Trials as Topic; Double-Bli | 1989 |
40 other studies available for 4-aminopyridine and Eaton-Lambert Myasthenic Syndrome
| Article | Year |
|---|---|
Aminopiridines in the treatment of multiple sclerosis and other neurological disorders.
Topics: 4-Aminopyridine; Aminopyridines; Humans; Lambert-Eaton Myasthenic Syndrome; Multiple Sclerosis; Nerv | 2020 |
Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports.
Topics: 4-Aminopyridine; Activities of Daily Living; Adult; Amifampridine; Azathioprine; Drug Therapy, Combi | 2017 |
The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome.
Topics: 4-Aminopyridine; Amifampridine; Direct-to-Consumer Advertising; Drug Compounding; Humans; Lambert-Ea | 2018 |
[A retrospective study of the effects of 3,4-diaminopyridine treatment in Lambert-Eaton myasthenic syndrome].
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Male | 2018 |
3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Cholinesterase Inhibitors; Female; Humans; Lambert-Eato | 2018 |
3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome: Concerns regarding presentation of previous studies.
Topics: 4-Aminopyridine; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Muscle Weakness; Potassiu | 2018 |
Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist.
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium Channel Agonists; Cell Line, Tumor; Drug Synergism; | 2014 |
Long-term observation of incremental response and antibodies to voltage-gated calcium channels in patients with Lambert-Eaton myasthenic syndrome: two case reports.
Topics: 4-Aminopyridine; Adult; Amifampridine; Calcium Channels; Follow-Up Studies; Humans; Immunoglobulins, | 2015 |
Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Female; Humans; Lambert-Eaton Myasthenic Syndrome | 2016 |
[A case of Lambert-Eaton myasthenic syndrome with small cell lung cancer, treated with 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Aged; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Mal | 2009 |
The price you pay.
Topics: 4-Aminopyridine; Amifampridine; Drug Approval; Drug Costs; European Union; Humans; Lambert-Eaton Mya | 2010 |
Orphan drugs. BioMarin Europe replies.
Topics: 4-Aminopyridine; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Orphan Drug Production; P | 2010 |
Content variability of active drug substance in compounded oral 3,4-diaminopyridine products.
Topics: 4-Aminopyridine; Administration, Oral; Amifampridine; Chromatography, High Pressure Liquid; Drug Com | 2012 |
Calcium channel subtypes contributing to acetylcholine release from normal, 4-aminopyridine-treated and myasthenic syndrome auto-antibodies-affected neuromuscular junctions.
Topics: 4-Aminopyridine; Acetylcholine; Adult; Aged; Aged, 80 and over; Animals; Autoantibodies; Calcium Cha | 2002 |
Myasthenia gravis and Lambert-Eaton myasthenic syndrome in the same patient.
Topics: 4-Aminopyridine; Adolescent; Amifampridine; Cholinesterase Inhibitors; Electrodiagnosis; Female; Hum | 2007 |
[Successful treatment of a Lambert-Eaton myasthenic syndrome patient with 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Amifampridine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposi | 2007 |
[Lambert-Eaton Myasthenic Syndrome associated with vocal cord carcinoma].
Topics: 4-Aminopyridine; Amifampridine; Carcinoma, Squamous Cell; Cholinesterase Inhibitors; Electrophysiolo | 2008 |
Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Aged; Amifampridine; Female; Heart Arrest; Humans; Iatrogenic Disease; Lambert-Eato | 1995 |
[Lambert-Eaton myasthenic syndrome: response to treatment with 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Aged; Amifampridine; Carcinoma, Small Cell; Humans; Lambert-Eaton Myasthenic Syndro | 1995 |
Lambert-Eaton myasthenic syndrome: evaluation of movement performance following drug therapy.
Topics: 4-Aminopyridine; Action Potentials; Adult; Amifampridine; Combined Modality Therapy; Electric Stimul | 1994 |
Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Clinical Protocols; Drug Synergism; Drug Therapy, Combination; Human | 1993 |
[The treatment of the Eaton-Lambert myasthenic syndrome with 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Amifampridine; Carcinoma, Small Cell; Drug Evaluation; Humans; Lambert-Eaton Myasth | 1993 |
[3,4-diaminopyridine in the treatment of myasthenic syndromes. Practical aspects].
Topics: 4-Aminopyridine; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Myasthenia Gravis; Potass | 1996 |
Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome before and after 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Adult; Amifampridine; Electromyography; Female; Humans; Lambert-Eaton Myasthenic Sy | 1997 |
Single-fiber electromyography improvement with 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Aged; Amifampridine; Electromyography; Humans; Lambert-Eaton Myasthenic Syndrome; M | 1998 |
3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
Topics: 4-Aminopyridine; Administration, Oral; Amifampridine; Animals; Follow-Up Studies; Humans; Lambert-Ea | 1998 |
A treatment algorithm for Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Algorithms; Amifampridine; Azathioprine; Carcinoma, Small Cell; Clinical Protocols; | 1998 |
Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Amifampridine; Autoantibodies; Carcinoma, Small Cell; Chil | 1998 |
Wide spectrum of symptomatic treatment in Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Carcinoma, Small Cell; Female; Guanidine; Humans; Lambe | 1998 |
Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Diagnosis, Differential; Electric Stimulation; Electrod | 1998 |
Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Action Potentials; Adult; Aged; Amifampridine; Female; Fingers; Humans; Lambert-Eat | 1998 |
Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Aged, 80 and over; Amifampridine; Carcinoma, Small Cell; C | 2000 |
Neurogenic bladder in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Aged; Amifampridine; Electromyography; Female; Humans; Lambert-Eaton Myasthenic Syn | 2001 |
[Quantitative evaluation of the effect of 3,4-diaminopyridine in a patient with Lambert-Eaton myasthenic syndrome using dynamic dynamometry].
Topics: 4-Aminopyridine; Action Potentials; Aged; Amifampridine; Electrophysiology; Female; Humans; Knee; La | 2001 |
[Long-term treatment of Lambert-Eaton syndrome by 3, 4 diaminopyridine].
Topics: 4-Aminopyridine; Amifampridine; Electromyography; Humans; Lambert-Eaton Myasthenic Syndrome; Male; M | 1992 |
Therapeutic approaches to Lambert-Eaton myasthenic syndrome in the intra-individual comparison.
Topics: 4-Aminopyridine; Amifampridine; Combined Modality Therapy; Electromyography; Follow-Up Studies; Guan | 1991 |
The myasthenic syndrome: anaesthesia in a patient treated with 3.4 diaminopyridine.
Topics: 4-Aminopyridine; Aged; Amifampridine; Anesthesia, General; Glycopyrrolate; Humans; Lambert-Eaton Mya | 1990 |
Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma.
Topics: 4-Aminopyridine; Action Potentials; Adult; Aged; Amifampridine; Carcinoma, Small Cell; Combined Moda | 1990 |
Lambert Eaton syndrome: autonomic neuropathy and inappropriate antidiuretic hormone secretion in a patient with small cell carcinoma of the lung.
Topics: 4-Aminopyridine; Aged; Amifampridine; Carcinoma, Small Cell; Humans; Inappropriate ADH Syndrome; Lam | 1990 |
[Lambert-Eaton myasthenic syndrome].
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Amifampridine; Antibodies, Antinuclear; Child; Electromyog | 1990 |